Adjuvant treatment: Clinical Trials

8 trials of Adjuvant treatment, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 not yet recruiting, 2 recruiting, 2 unknown, 1 completed. 6 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Not yet recruiting 2, Recruiting 2, Terminated 1, Unknown 1
Phase 32Completed 1, Recruiting 1

Follow Adjuvant treatment: new trials by email Literature Review of Adjuvant treatment trials Research Report on Adjuvant treatment

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study.
Pembrolizumab neoadjuvant treatment, surgery, Adjuvant treatment - Stage IIB Melanoma, Stage IIC Melanoma
Phase 2Not yet recruitingCentre Hospitalier Universitaire de Besancon192026-11-012026-10-20
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
Adebrelimab, Adjuvant treatment - Lung Neoplasm Malignant
Phase 2Not yet recruitingRuijin Hospital642026-10-202026-10-22
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Radiation Therapy, Chemoradiotherapy, Consolidation Chemotherapy - Rectal Cancer, Total Neoadjuvant Treatment
Phase 2 / Phase 3RecruitingNational Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos4002025-01-062026-05-11
Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer
salvage surgery - Locally Recurrent Colorectal Cancer
UnknownCancer Institute and Hospital, Chinese Academy of Medical Sciences5002023-01-302023-11-02
Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas
Neoadjuvant treatment, Adjuvant treatment - Neuroendocrine Carcinoma, Digestive Cancer
Phase 2RecruitingGERCOR - Multidisciplinary Oncology Cooperative Group782021-01-052025-07-23
Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma
adjuvant treatment - Esophageal Squamous Cell Carcinoma
Phase 3CompletedFujian Medical University Union Hospital1452019-08-232026-10-28
Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer
Neoadjuvant chemoradiotherapy, Adjuvant chemoradiotherapy - Esophageal Cancer
Phase 2UnknownZhejiang Cancer Hospital602011-10-012013-05-14
Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)
Sunitinib, Placebo - Renal Cell Carcinoma, Pulmonary Metastases
Phase 2TerminatedAssociation of Urologic Oncology (AUO)602010-10-012026-08-25

Conditions studied

Carcinoma (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Esophageal Neoplasms (1)  ·  Esophageal Squamous Cell Carcinoma (1)  ·  Fatigue (1)  ·  Gastrointestinal Neoplasms (1)  ·  Low Anterior Resection Syndrome (1)  ·  Lung Neoplasms (1)  ·  Melanoma (1)  ·  Neoplasm Metastasis (1)  ·  Postoperative Complications (1)  ·  Radiation Injuries (1)  ·  Rectal Neoplasms (1)

Sponsors

Association of Urologic Oncology (AUO) (1)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  Centre Hospitalier Universitaire de Besancon (1)  ·  Fujian Medical University Union Hospital (1)  ·  GERCOR - Multidisciplinary Oncology Cooperative Group (1)  ·  National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos (1)  ·  Ruijin Hospital (1)  ·  Zhejiang Cancer Hospital (1)

Countries

China (4)  ·  France (2)  ·  Germany (1)  ·  Lithuania (1)

Top investigators

Audrius Dulskas, PhD (1)  ·  Chun Chen, MD (1)  ·  Hecheng Li, MD, PhD (1)  ·  Jingyuan Fan, MD, PhD (1)  ·  Runsen Jin, MD, PhD (1)  ·  Susanne Krege, Priv. Doz. Dr. med. (1)  ·  Weimin Mao, MD (1)  ·  Yichao Han, MD, PhD (1)  ·  Zhaoxu Zheng, M.D. (1)

Results publications

PMID 16971718, PMID 17008704

NIH funding

2008 (1)